Clinical Application of AMH Measurement in Assisted Reproduction
Anti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction mod...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.606744/full |
| _version_ | 1818352911612116992 |
|---|---|
| author | Hang Wun Raymond Li Scott M. Nelson Scott M. Nelson Scott M. Nelson |
| author_facet | Hang Wun Raymond Li Scott M. Nelson Scott M. Nelson Scott M. Nelson |
| author_sort | Hang Wun Raymond Li |
| collection | DOAJ |
| description | Anti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction models it has limited ability to predict live birth and should not be used to refuse treatment, but rather to inform counselling and shared decision making. The use of absolute clinical thresholds to stratify patient phenotypes, assess discordance and individualize treatment protocols in non-validated algorithms combined with the lack of standardization of assays may result in inappropriate classification and sub-optimal clinical decision making. We propose that holistic baseline phenotyping, incorporating antral follicle count and other patient characteristics is critical. Treatment decisions driven by validated algorithms that use ovarian reserve biomarkers as continuous measures, reducing the risk of misclassification, are likely to improve overall outcomes for our patients. |
| first_indexed | 2024-12-13T19:01:09Z |
| format | Article |
| id | doaj.art-9a078673f13a41789a66ddeeb4f5f6ce |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-13T19:01:09Z |
| publishDate | 2020-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-9a078673f13a41789a66ddeeb4f5f6ce2022-12-21T23:34:40ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922020-12-011110.3389/fendo.2020.606744606744Clinical Application of AMH Measurement in Assisted ReproductionHang Wun Raymond Li0Scott M. Nelson1Scott M. Nelson2Scott M. Nelson3Department of Obstetrics and Gynaecology, The University of Hong Kong, Pokfulam, Hong KongSchool of Medicine, University of Glasgow, Glasgow, Scotland, United KingdomNIHR Bristol Biomedical Research Centre, Bristol, United KingdomThe Fertility Partnership, Oxford, United KingdomAnti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction models it has limited ability to predict live birth and should not be used to refuse treatment, but rather to inform counselling and shared decision making. The use of absolute clinical thresholds to stratify patient phenotypes, assess discordance and individualize treatment protocols in non-validated algorithms combined with the lack of standardization of assays may result in inappropriate classification and sub-optimal clinical decision making. We propose that holistic baseline phenotyping, incorporating antral follicle count and other patient characteristics is critical. Treatment decisions driven by validated algorithms that use ovarian reserve biomarkers as continuous measures, reducing the risk of misclassification, are likely to improve overall outcomes for our patients.https://www.frontiersin.org/articles/10.3389/fendo.2020.606744/fullanti-Müllerian hormoneassisted reproductionin vitro fertilizationintrauterine inseminationovarian responsegonadotropin dosing |
| spellingShingle | Hang Wun Raymond Li Scott M. Nelson Scott M. Nelson Scott M. Nelson Clinical Application of AMH Measurement in Assisted Reproduction Frontiers in Endocrinology anti-Müllerian hormone assisted reproduction in vitro fertilization intrauterine insemination ovarian response gonadotropin dosing |
| title | Clinical Application of AMH Measurement in Assisted Reproduction |
| title_full | Clinical Application of AMH Measurement in Assisted Reproduction |
| title_fullStr | Clinical Application of AMH Measurement in Assisted Reproduction |
| title_full_unstemmed | Clinical Application of AMH Measurement in Assisted Reproduction |
| title_short | Clinical Application of AMH Measurement in Assisted Reproduction |
| title_sort | clinical application of amh measurement in assisted reproduction |
| topic | anti-Müllerian hormone assisted reproduction in vitro fertilization intrauterine insemination ovarian response gonadotropin dosing |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2020.606744/full |
| work_keys_str_mv | AT hangwunraymondli clinicalapplicationofamhmeasurementinassistedreproduction AT scottmnelson clinicalapplicationofamhmeasurementinassistedreproduction AT scottmnelson clinicalapplicationofamhmeasurementinassistedreproduction AT scottmnelson clinicalapplicationofamhmeasurementinassistedreproduction |